Clarity Pharmaceuticals Ltd

OTCPK:CLRP.F Stock Report

Market Cap: US$818.9m

Clarity Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:CLRP.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
23 Sep 24BuyUS$2,573,027Bank of America Corporation, Asset Management ArmCompany444,419US$5.79
23 Sep 24SellUS$1,437,241Bank of America Corporation, Asset Management ArmCompany250,293US$5.74
20 Sep 24BuyUS$32,351Merrill Lynch & Co. Inc., Banking InvestmentsCompany5,479US$5.90
20 Sep 24SellUS$1,044,856Merrill Lynch & Co. Inc., Banking InvestmentsCompany185,399US$5.64
17 Sep 24BuyUS$37,536,195Bank of America Corporation, Asset Management ArmCompany10,426,657US$3.60
17 Sep 24SellUS$28,593,837Bank of America Corporation, Asset Management ArmCompany7,362,426US$3.88
12 Sep 24BuyUS$1,689,275Merrill Lynch & Co. Inc., Banking InvestmentsCompany409,239US$4.13
03 Sep 24SellUS$1,072,183Merrill Lynch & Co. Inc., Banking InvestmentsCompany221,711US$4.84
20 May 24BuyUS$45,410Robert ThomasIndividual15,908US$2.94
29 Apr 24BuyUS$57,025Robert ThomasIndividual34,092US$1.67

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CLRP.F?
Owner TypeNumber of SharesOwnership Percentage
State or Government3,599,9201.12%
Private Companies35,448,46211%
Institutions42,372,08613.2%
Individual Insiders57,135,85817.8%
General Public182,254,53756.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.3%.

Top Shareholders

Top 25 shareholders own 42.89% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.65%
Christopher Roberts
18,111,280US$46.2m1.12%no data
5.21%
TM Ventures Pty Ltd.
16,699,842US$42.6m-11.1%no data
4.89%
Alan Taylor
15,693,438US$40.1m7.42%no data
4.63%
The Vanguard Group, Inc.
14,867,472US$37.9m0.44%no data
3.06%
Argo Investments Limited
9,802,322US$25.0m-2.49%0.5%
2.51%
Yarrawah Pty Ltd
8,040,000US$20.5m3.03%no data
2.12%
Vantres Pty Ltd
6,812,340US$17.4m-9.02%no data
2.06%
Charles Morgan
6,600,041US$16.8m0%no data
1.89%
Matthew Harris
6,065,800US$15.5m0%no data
1.56%
Smarter Capital Pty Ltd
5,004,543US$12.8m0%no data
1.46%
Bank of America Corporation, Asset Management Arm
4,675,014US$11.9m0%no data
1.35%
Colin Biggin
4,334,085US$11.1m33.4%no data
1.21%
Kylaco Pty Ltd
3,896,280US$9.9m0%no data
1.12%
Australian Nuclear Science and Technology Organisation
3,599,920US$9.2m0%no data
1%
BlackRock, Inc.
3,222,640US$8.2m31.7%no data
1%
Guido Belgiorno-Nettis
3,210,425US$8.2m3.03%no data
0.36%
Robert Thomas
1,145,000US$2.9m0%no data
0.34%
Michelle Parker
1,077,710US$2.8m101%no data
0.29%
Portland Investment Counsel Inc.
929,235US$2.4m132%0.69%
0.26%
State Street Global Advisors, Inc.
846,990US$2.2m343%no data
0.26%
BetaShares Capital Limited
818,398US$2.1m24%0.01%
0.22%
Thomas Ramdahl
720,000US$1.8m38.5%no data
0.17%
Merrill Lynch & Co. Inc., Banking Investments
548,412US$1.4m0%no data
0.16%
Charles Schwab Investment Management, Inc.
517,012US$1.3m-0.35%no data
0.11%
Norges Bank Investment Management
367,730US$938.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 23:02
End of Day Share Price 2025/01/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clarity Pharmaceuticals Ltd is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Madeleine WilliamsCanaccord Genuity
David StantonJefferies LLC